BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Bright Minds Biosciences (DRUG) added ~10% in the premarket on Tuesday after the company said that its lead asset, BMB-101, ...

The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline. ・In the Absence cohort, patients experienced a median 73.1% reduction in seizures. ・The DEE cohort saw a ...

Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...

(NewsNation) — March 26 is Purple Day, a day dedicated to raising awareness about epilepsy worldwide. An estimated 50 million people worldwide are diagnosed with epilepsy, and seizures are the main ...

Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...